Deepa Subramaniam, M.D., M.S., an internationally respected neuro-oncologist and clinical researcher, has joined Revolution Medicines as Vice President and Head of Early-Stage Clinical Development. With more than two decades of experience spanning academic medicine, early-phase trials, and translational drug development, Dr. Subramaniam brings a proven track record of advancing therapies for patients with some of the most challenging malignancies, including RAS-driven cancers and primary and metastatic brain tumors.
“It has been two weeks since I joined the Revolutionaries in the fight against RAS-addicted cancers. I am thrilled to share that I have joined Revolution Medicines as Vice President and Head of Early-Stage Clinical Development. I am eager to contribute to the advancement of the company’s pioneering work in historically challenging cancers. Building and shaping a talented early oncology community of drug developers and driving innovation forward will be my top priorities.”
Her appointment marks a significant step in Revolution Medicines’ strategic expansion in early oncology, reinforcing the company’s commitment to developing novel targeted therapies for historically hard-to-treat cancers.
Education and Training
Dr. Deepa Subramaniam earned her medical degree from Government Kilpauk Medical College in 1995. She completed her residency in internal medicine at Providence Hospital in Washington, D.C., in 2002, and pursued a clinical fellowship in hematology and medical oncology at Georgetown University/MedStar Health from 2004 to 2007. She is board-certified in internal medicine, hematology, and medical oncology, holding licensure through the District of Columbia Board of Medicine. These credentials reflect her extensive expertise in comprehensive cancer care and her longstanding commitment to medical excellence.
Clinical Expertise and Practice
Dr. Deepa Subramaniam practices at the Georgetown Lombardi Comprehensive Cancer Center in Burleith and Washington, D.C., where she has contributed significantly to advancing oncology care. Her clinical expertise spans neuro-oncology, thoracic cancers, hematologic malignancies, and genitourinary oncology. She is highly skilled in the diagnosis and management of complex cancers, employing a wide range of tools including biopsies, imaging, endoscopies, chemotherapy, and coordination of radiation therapy. Dr. Subramaniam’s primary clinical interests focus on lung cancer and brain tumors, areas in which she has established a reputation for both clinical acumen and compassionate patient care.
Research Contributions
Throughout her career, Dr. Deepa Subramaniam has contributed to the scientific understanding of molecular diagnostics, targeted therapies, and early-phase clinical trials, particularly in the context of lung cancer and neuro-oncology. Her work has addressed resistance mechanisms to targeted therapy, the integration of biomarkers into clinical practice, and the development of novel therapeutic strategies for historically difficult-to-treat tumors. Among her notable publications are studies on EGFR-mutant non-small-cell lung cancer, BRAF-mutant metastatic lung adenocarcinoma, and the use of immune checkpoint inhibitors in rare thoracic malignancies. She has also explored molecular diagnostics and targeted therapy applications, helping to define precision oncology approaches for advanced solid tumors.
Some of her most influential publications include a Phase I trial of Dasatinib and Osimertinib in EGFR-mutant non-small-cell lung cancer, studies on pembrolizumab in thymic carcinoma, and work examining resistance to lung cancer targeted therapies. These contributions have been published in top-tier journals such as Frontiers in Oncology, The Lancet Oncology, Discovery Medicine, and the Journal of Thoracic Oncology, among others.
Leadership and Recognition
Dr. Deepa Subramaniam has been recognized throughout her career for her excellence in patient care, teaching, and community engagement. She has received the Top Fundraising Team Award in 2017, the Triumph of the Spirit Award for Excellence in Brain Tumor Care in 2014, the Teaching Excellence Award in 2013, and the Hattie McDaniels Health Award in 2011. Her leadership extends beyond clinical practice to mentoring trainees, shaping early-phase clinical trials, and contributing to multidisciplinary tumor boards and collaborative research initiatives.
Patient-Centered Philosophy
Central to Dr. Deepa Subramaniam’s practice is a philosophy of treating each patient with compassion, respect, and dignity. She emphasizes effective communication, patient education, and supportive care, focusing on alleviating pain and improving quality of life throughout treatment. Her approach reflects a holistic view of cancer care, integrating scientific innovation with personalized patient support.
For the latest oncology news and expert insights, read more on OncoDaily
Written by Nare Hovhannisyan, MD